These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1341252)

  • 1. A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma.
    Geiger JD; Wagner PD; Shu S; Chang AE
    Surg Oncol; 1992 Jun; 1(3):199-208. PubMed ID: 1341252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
    Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
    Krauss JC; Strome SE; Chang AE; Shu S
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
    Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
    Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma.
    Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S; Kondo M
    Int J Immunopharmacol; 1996 Feb; 18(2):141-53. PubMed ID: 8799364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene.
    Wahl WL; Strome SE; Nabel GJ; Plautz GE; Cameron MJ; San H; Fox BA; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):1-11. PubMed ID: 7728301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S; Sussman JJ; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma.
    Strome SE; Martin B; Flies D; Tamada K; Chapoval AI; Sargent DJ; Shu S; Chen L
    J Immunother; 2000; 23(4):430-7. PubMed ID: 10916752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
    Winter H; Hu HM; Poehlein CH; Huntzicker E; Osterholzer JJ; Bashy J; Lashley D; Lowe B; Yamada J; Alvord G; Urba WJ; Fox BA
    Immunology; 2003 Mar; 108(3):409-19. PubMed ID: 12603608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
    Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
    J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy of poorly immunogenic tumors with in vitro sensitized cells generated by intratumoral administration of biological response modifiers.
    Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S
    Int J Immunopharmacol; 1995 Dec; 17(12):963-71. PubMed ID: 8964655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.